KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Capital Expenditures: 2011-2024

Historic Capital Expenditures for Esperion Therapeutics (ESPR) over the last 11 years, with Dec 2024 value amounting to $317,000.

  • Esperion Therapeutics' Capital Expenditures was N/A to $150,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $493,000, marking a year-over-year change of. This contributed to the annual value of $317,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Capital Expenditures is $317,000, which was down 63.52% from $869,000 recorded in FY2020.
  • Esperion Therapeutics' 5-year Capital Expenditures high stood at $869,000 for FY2020, and its period low was $317,000 during FY2024.
  • For the 1-year period, Esperion Therapeutics' Capital Expenditures averaged around $317,000, with its median value being $317,000 (2024).
  • Data for Esperion Therapeutics' Capital Expenditures shows a maximum YoY declined of 8.81% (in 2020) over the last 5 years.
  • Esperion Therapeutics' Capital Expenditures (Yearly) stood at $869,000 in 2020, then followed by $317,000 in 2024.